Search

Displaying results 5611 - 5620 of 8697 in total
  1. Drug

    Sinapultide

    go.drugbank.com/drugs/DB11332
    ApprovedWithdrawn

    [L2502] Windtree Therapeutics plans a phase III trial for Respiratory distress syndrome in 2018.

  2. Drug

    Aluminum zirconium trichlorohydrex gly

    go.drugbank.com/drugs/DB11116
    ApprovedWithdrawn

    Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.

  3. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis.

  4. Drug

    Pirbuterol

    go.drugbank.com/drugs/DB01291
    ApprovedWithdrawn

    Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is reco...

    Categories: Adrenergics for Systemic Use, Drugs for Obstructive Airway Diseases
  5. Drug

    BB 21217

    go.drugbank.com/drugs/DB17373
    Investigational

    ) for memory-like T cells. … BB 21217 is an anti-BCMA CAR T cell therapy that uses the same CAR molecule as [idecabtagene vicleucel] (bb2121), but adds the PI3K inhibitor bb007 during ex vivo culture to enrich the drug product (DP

  6. Drug

    RGX-501

    go.drugbank.com/drugs/DB17639
    Investigational

    It is being investigated for the treatment of homozygous familial hypercholesterolemia.[L46696] … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells.

  7. Drug

    Dabocemagene autoficel

    go.drugbank.com/drugs/DB17878
    Investigational

    Developed by Castle Creek Biosciences Inc., dabocemagene autoficel is being investigated for the treatment of dystrophic epidermolysis bullosa.[L46797] … Dabocemagene autoficel is an _ex vivo_, autologous cell-based gene therapy. It comprises autologous dermal fibroblasts genetically modified to express functional type VII collagen.

    Synonyms: TRANSDUCED HUMAN AUTOLOGOUS DYSTROPHIC EPIDERMOLYSIS BULLOSA DERMAL FIBROBLAST CELL FCX-007 INTEGRATED PROVIRAL HUMAN COLLAGEN TYPE VII TRANSGENE COL7A1 PLUS 5'-HUMAN CYTOMEGALOVIRUS PROMOTER/UTR-AND 3'-LTR/PO
  8. Drug

    Viralym-C

    go.drugbank.com/drugs/DB17975
    Investigational

    It was granted FDA orphan designation in January 2017 and investigated for the treatment of CMV infection.[A260291, L47241] … Viralym-C is an investigational T-cell immunotherapy developed by ViraCyte. It consists of Human Leukocyte Antigen (HLA)-matched cytomegalovirus (CMV)-specific T lymphocytes.

  9. Drug

    BO-653

    go.drugbank.com/drugs/DB19216
    Investigational

    BO-653 is under investigation in clinical trial NCT00055510 (A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and

  10. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment. … A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient.